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Summary
Platelet responses to activating agonists are influenced by common 
population variants within or near G protein-coupled receptor (GPCR) 
genes that affect receptor activity. However, the impact of rare GPCR 
gene variants is unknown. We describe the rare single nucleotide vari-
ants (SNVs) in the coding and splice regions of 18 GPCR genes in 
7,595 exomes from the 1,000-genomes and Exome Sequencing 
 Project databases and in 31 cases with inherited platelet function dis-
orders (IPFDs). In the population databases, the GPCR gene target 
 regions contained 740 SNVs (318 synonymous, 410 missense, 7 stop 
gain and 6 splice region) of which 70 % had global minor allele fre-
quency (MAF) < 0.05 %. Functional annotation using six computation-
al algorithms, experimental evidence and structural data identified 
156/740 (21 %) SNVs as potentially damaging to GPCR function, most 
commonly in regions encoding the transmembrane and C-terminal in-
tracellular receptor domains. In 31 index cases with IPFDs (Gi-path-
way defect n=15; secretion defect n=11; thromboxane pathway de-
fect n=3 and complex defect n=2) there were 256 SNVs in the target 
regions of 15 stimulatory platelet GPCRs (34 unique; 12 with 
MAF< 1 % and 22 with MAF≥ 1 %). These included rare variants pre-
dicting R122H, P258T and V207A substitutions in the P2Y12 receptor 
that were annotated as potentially damaging, but only partially ex-
plained the platelet function defects in each case. Our data highlight 
that potentially damaging variants in platelet GPCR genes have low 
individual frequencies, but are collectively abundant in the population. 
Potentially damaging variants are also present in pedigrees with IPFDs 
and may contribute to complex laboratory phenotypes.
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Introduction
G protein-coupled receptors (GPCRs) are seven transmembrane 
domain proteins that mediate signal transduction from a wide 
range of extracellular stimuli. GPCRs are expressed widely in hae-
matopoietic and vascular tissues, including platelets, in which they 
mediate activation signals from agonists such as thrombin (pro-
tease activated receptors [PAR] 1 and 4), thromboxane A2 
(thromboxane A2 receptor [TP]), epinephrine (α2A-adrenorecep-
tor) and ADP (P2Y12 and P2Y1 receptors). Platelets also express Gs-
coupled GPCRs such as the prostacyclin (IP1), adenosine 2A (A2A) 
and prostaglandin D2 (DP1) receptors, which mediate inhibitory 
signals from prostacyclin, adenosine and PGD2 respectively, to 
suppress platelet activation.
Platelet GPCR activity varies between individuals within the 
population, in part because of common genetic sequence variants 
(minor allele frequency (MAF) ≥ 1.0 %) near, or within GPCR 
genes. Examples include the variant rs1472122 (downstream of the 
P2Y12 gene P2RY12), which affects ADP-induced platelet fibri-
nogen binding and P-selectin exposure (1) and the variant 
rs4311994 (downstream of the α2A-adrenoreceptor gene 
ADRA2A), which affects epinephrine-induced platelet aggregation 
(2). Similar associations have been demonstrated between com-
mon variants in the PAR1 (F2R), PAR4 (F2RL3) and the TP recep-
tor (TBXA2R) genes and function of the corresponding GPCRs 
(3–5). Some common variants also influence susceptibility to car-
diovascular disease and responses to anti-platelet drugs (4–6). 
Since the common GPCR gene variants lie exclusively in non-
coding regions, these effects are most likely caused by changes in 
receptor expression, and not altered receptor function (4, 7).
Although the evidence linking common variants near platelet 
GPCR genes and GPCR activity is compelling, the individual effect 
size of common variants is small (2). For other genes, rare (MAF 
< 1 %) single nucleotide variants (SNVs), with large individual 
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 effect size, provide a greater source of inter-individual genetic vari-
ation than common variants (8–10). However, for platelet GPCR 
genes, descriptions of rare variants affecting platelet function are 
restricted to SNVs in P2RY12 and TBXA2R in isolated pedigrees 
with inherited platelet function disorders (IPFD) (11–17). It is 
likely that the impact of rare GPCR gene variants in the population 
is much greater than implied from these limited descriptions, but 
this has not been confirmed by systematic analysis. In order to as-
sess the population diversity and impact of rare SNVs in platelet 
GPCR genes, we have surveyed and annotated coding and splice 
region SNVs in public databases of 7595 individuals and in 31 
cases with IPFD of unknown genetic basis.
Materials and methods
G protein-coupled receptors in human platelets
Class A GPCRs that were listed in the International Union of Basic 
and Clinical Pharmacology (IUPHAR) GPCR Database (Suppl. 
Table 1, available online at www.thrombosis-online.com) were se-
lected for analysis if present in the Proteomics Identifications Da-
tabase (PRIDE), the PlateletWeb resource (Suppl. Table 1, available 
online at www.thrombosis-online.com) and in the human platelet 
transcriptome with > 1.0 reads per kilobase of exon model per mil-
lion mapped reads (18).
GPCR gene variations in population datasets
We identified coding sequence and splice region (from 3 exonic to 
8 intronic nucleotides flanking the exon-intron boundaries) SNVs 
in the GPCR gene shortlist in the April 2012 Integrated Variant Set 
release of the 1,000 Genomes project and the NHLBI Exome Se-
quencing Project (ESP) dataset release number ESP6500, accessed 
through Ensembl Variation 74 (H. sapiens Short Variation 
GRCh37.p13 dataset) using the BioMart tool (Suppl. Table 1, avail-
able online at www.thrombosis-online.com). Nucleotide variations 
were annotated to the consensus coding sequence (CCDS) data-
base transcript of each platelet GPCR.
GPCR gene variations in inherited platelet function 
disorders
Genomic DNA was isolated from peripheral venous blood from a 
representative sub-group of 31 unrelated cases with IPFD re-
cruited at UK Haemophilia Comprehensive Care Centres to the 
Genotyping and Phenotyping of Platelets (GAPP) study (ISRCTN 
77951167, UK REC 06/MRE07/36) according to previously re-
ported eligibility criteria (19). For all cases, platelet function was 
evaluated using light transmission aggregation and ATP secretion 
assays using nine agonists at least two weeks after exposure to 19 
drugs known to affect platelet function (19, 20). Genomic DNA 
was enriched for the target GPCR genes either using a custom 
made bait library for platelet genes (21) or the Agilent SureSelect 
All Exon 50Mb kit (Agilent Technologies, Wokingham, UK). Se-
quence data were captured using an Illumina HiSeq 2000 analyser 
(Illumina Inc San Diego, CA, USA). Sequence reads were mapped 
to the reference genome GRCh37.p11, Feb 2009 and SNVs were 
annotated to the consensus CCDS records using the ANNOVAR 
tool (Suppl. Table 1, available online at www.thrombosis-online.
com). Since the IPFD cases all showed reduced platelet responses, 
we analysed stimulatory platelet GPCRs and excluded the Gs-
coupled inhibitory GPCRs IP1, DP1 receptor and A2A receptor. All 
potentially damaging SNVs were confirmed by PCR amplification 
of individual exons and direct cycle sequencing.
Functional annotation of GPCR gene variants using 
computational algorithms
SNVs that were identified in population databases and in cases 
with IPFD were classified according to sequence ontology termi-
nology used in Ensembl release 74 (Suppl. Table 1, available online 
at www.thrombosis-online.com). The likely pathogenicity of each 
SNV was determined using the MAPP, PhD-SNP, PolyPhen-1, 
PolyPhen-2, SIFT and SNAP prediction tools on the PredictSNP 
server (Suppl. Table 1, available online at www.thrombosis-online.
com). SNVs were classified as potentially damaging if identified as 
‘damaging’ by the PredictSNP meta-analysis tool with a consensus 
likelihood of > 0.5 (22). Splice region variants were analysed using 
the Human SpliceFinder tool (Suppl. Table 1, available online at 
www.thrombosis-online.com) and were classified as potentially 
damaging if the difference between the splice site prediction scores 
of the wild type and variant sequences exceeded 30 % that of the 
wild-type sequence (23).
Manual functional annotation of GPCR gene variants
Missense SNVs were also annotated using a manual strategy in 
which variants were classified as potentially damaging if any of the 
following criteria were met:
• The substituted amino-acid was within a functional GPCR se-
quence motif identified in UniProt (Suppl. Tables 1 and 2, avail-
able online at www.thrombosis-online.com).
• The substituted amino-acid, expressed in Ballesteros-Weinstein 
nomenclature, (24) contributed to inter-helical interactions, the 
ligand binding pocket or to the G-protein binding sites in the 
consensus Class A GPCR structure (25) or in published crystal 
structures for the PAR1 (26), A2A (27) or P2Y12 receptors (28) 
(Suppl. Table 2, available online at www.thrombosis-online.
com).
• There was published experimental evidence of a change in 
GPCR function from site-directed mutagenesis in a heterolo-
gous system, determined from the GPCRDB resource (Suppl. 
Table 1, available online at www.thrombosis-online.com).
Analysis of the P2Y12 R122H and V207A variants in 
transfected cells
R122H and V207A HA-tagged human P2Y12 constructs were gen-
erated by site-directed mutagenesis (Eurofins MWG Operon, 
Ebersberg, Germany) and were transfected into either HEK293 or 
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Table 1: Platelet G-protein coupled receptors. The table lists the 18 G protein-coupled receptors described in IUPHAR terminology, listed in order of de-
creasing transcript abundance in human megakaryocytes (18). †Principal coupled G protein. ‡Major CCDS annotated transcript with experimental evidence in 
megakaryocytes.
Gene Name
F2R
P2RY12
PTGIR
TBXA2R
LPAR5
ADORA2A
CXCR4
F2RL3
P2RY1
ADRA2A
CCR4
PTGDR
AVPR1A
PTAFR
FPR1
PTGER3
SUCNR1
HTR2A
Receptor Name
PAR1
P2Y12
IP1
TPα
LPA5
A2A receptor
CXCR4
PAR4
P2Y1
α2A-adrenoceptor
CCR4
DP1 receptor
V1A receptor
PAF receptor
FPR1
EP3 receptor
succinate receptor
5-HT2A receptor
GC content (%)
49.8
40.7
69.0
69.6
67.9
61.3
50.3
69.9
51.0
61.3
48.2
59.9
58.9
53.8
52.7
60.8
43.0
46.0
G-protein†
Gq
Gi
Gs
Gq
Gq
Gs
Gi
Gq
Gq
Gz
Gi
Gs
Gq
Gq
Gi
Gq
Gi
Gq
Protein Accession
ENSP00000321326
ENSP00000307259
ENSP00000291294
ENSP00000364336
ENSP00000327875
ENSP00000336630
ENSP00000241393
ENSP00000248076
ENSP00000304767
ENSP00000280155
ENSP00000332659
ENSP00000303424
ENSP00000299178
ENSP00000362965
ENSP00000471493
ENSP00000302313
ENSP00000355156
ENSP00000437737
Transcript Accession‡
ENST00000319211
ENST00000302632
ENST00000291294
ENST00000375190
ENST00000329858
ENST00000337539
ENST00000241393
ENST00000248076
ENST00000305097
ENST00000280155
ENST00000330953
ENST00000306051
ENST00000299178
ENST00000373857
ENST00000304748
ENST00000306666
ENST00000362032
ENST00000378688
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1321N1 cells according to previously described methods (17). Cell 
surface P2Y12 expression in the transfected cells was determined by 
enzyme linked immunosorbent assay (ELISA) and by immunoflu-
orescence microscopy using murine anti-HA antibody (HA-11) as 
described previously (17). P2Y12 receptor function was measured 
by incubating the transfected cells with 1 µM forsoklin (Sigma-Al-
drich, Gillingham, UK) to increase basal cAMP levels. The cells 
were then incubated with 50 µM-10 nM ADP before residual 
cAMP concentrations were determined in cell lysates by ELISA 
(Sigma-Aldrich cAMP Enzyme Immunoassay Kit, Gillingham, 
UK).
Results
Identification of GPCRs in human platelets
Using the IUPHAR database, we identified 18 Class A GPCRs with 
robust evidence of expression in human platelets at transcript and 
protein levels. The coding regions of the 18 GPCR genes had 
median length of 1121 kb (interquartile range [IQR] 1043–1248) 
and median GC content of 56.4 % (IQR 49.0–64.6; ▶ Table 1).
GPCR gene variations in population datasets
In order to assess the allelic diversity of the platelet GPCR genes, 
we surveyed the 1,000 genomes (1,092 subjects) and ESP (6,503 
subjects) datasets for coding and splice region SNVs in the 18 se-
lected GPCR genes. We identified 740 SNVs in the target regions 
(median 41.5 [IQR 30–48] SNVs per GPCR gene) of which 318 
(43 %) were synonymous, 410 (55 %) were missense and 7 (1 %) 
were stop-gain (▶ Figure 1 A). There were five intronic splice re-
gion SNVs and 1 exonic splice region SNV that was also a synony-
mous coding region SNV. Amongst the 740 SNVs in the target re-
gions, 58 (8 %) had global MAF ≥ 1 %, 163 (22 %) had MAF 
0.99–0.05 % and 519 (70 %) had global MAF < 0.05 % or were 
singletons, indicating very low population frequency.
Predicting the functional impact of GPCR gene 
 variants
We used both computational and manual annotation to assess 
whether missense SNVs in the GPCR gene target regions were po-
tentially damaging to GPCR function. Computational annotation 
using the PredictSNP server enabled meta-analysis of predictions 
from six tools that utilise trained decision (PhD-SNP, Polyphen-2 
and SNAP), evolutionary conservation (SIFT), physicochemical 
(MAPP) and expert rule (Polyphen-1) algorithms to generate a 
consensus likelihood of pathogenicity for each SNV (22). Using 
this strategy, 122 (30 %) of the 410 missense SNVs in the GPCR 
gene target regions were classified as potentially damaging (Suppl. 
Table 3, available online at www.thrombosis-online.com). None of 
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the six splice region SNVs were predicted by computation to dis-
rupt transcript splicing.
Our manual annotation strategy classified missense SNVs as 
potentially damaging if the predicted amino-acid substitution af-
fected a functional GPCR sequence motif or a critical residue in 
the consensus or specific GPCR crystal structures or if previous 
experimental mutagenesis of the residue caused loss of receptor 
function. This identified 60 (15 %) of the 410 missense SNVs in the 
GPCR gene target regions as potentially damaging (Suppl. Table 3, 
available online at www.thrombosis-online.com). Seven stop-gain 
SNVs were also classified as potentially damaging by manual an-
notation since they predicted protein truncation.
The total number of all classes of SNV that were classified as 
potentially damaging by either computational or manual anno-
tation was 156 (21 % of all SNVs; Suppl. Table 3, available online at 
www.thrombosis-online.com). Forty missense SNVs were classi-
Figure 1: Distribution 
of SNVs in the target 
regions of 18 platelet 
GPCR genes in the ESP 
and 1,000 genomes 
datasets. A) The total 
number of unique SNVs 
in each GPCR gene found 
in the population data-
sets, subdivided according 
to whether missense, syn-
onymous or stop-gain/
splice region. B) The total 
number of unique SNVs 
in the population data-
sets that were classified 
as potentially damaging, 
subdivided according to 
whether missense or 
stop-gain.
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Figure 2: Distribution of potentially damaging missense SNVs across 
GPCR domains. Schematic of a prototypical Class A GPCR showing the 
N-terminal extracellular region (NT), the transmembrane helices (TM1–7), 
the intracellular (IL) and extracellular (EL) loops, and the C-terminal intracel-
lular region (CT). The number of missense SNVs in the population databases 
classified as potentially damaging within these regions are represented in 
the bar chart.
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fied as potentially damaging by both computational and manual 
annotation (Suppl. Table 2, available online at www.thrombosis-on
line.com).
Distribution of damaging missense GPCR gene 
 variants
The 149 potentially damaging missense SNVs were represented in 
all of the 18 selected GPCR genes (▶ Figure 1 B) and predicted 
amino-acid substitutions that were more common in the TM do-
mains and C-terminal intracellular region (CT) than other regions 
(▶ Figure 2). Twenty-five SNVs predicted amino-acid substitu-
tions at sites shown in the consensus Class A GPCR structure to 
contribute to inter-helical interactions between the TM domains. 
A further 15 were in regions implicated in G protein interactions, 
five were in the helical regions of consensus ligand binding 
pockets, three were located in D/NPXXY motifs and one was in an 
E/DRY motif (▶ Table 2).
Characteristics of patients with inherited platelet 
function disorders
The IPFD collection comprised 31 unrelated cases (11 males and 
20 females; age range 6–82 years) with abnormal platelet function 
determined by light transmission aggregation and ATP release as-
says (19, 20). The collection comprised cases in which the main 
laboratory defect was within the Gi-pathway (n=15), secretion 
pathway (n=11) and thromboxane synthesis pathway (n=3) ac-
cording to previous diagnostic criteria (19). Two cases showed 
complex defects that could not be classified. This collection was 
selected as a representative sub-group of a larger collection of 111 
previously reported cases with inherited platelet function dis-
orders enrolled into the UK GAPP study and showed a similar dis-
tribution of pathway defects to the group as a whole (19).
GPCR gene variations in cases with inherited platelet 
disorders
Among the 31 cases with IPFD, we identified 256 SNVs in the tar-
get regions of the genes encoding the stimulatory platelet GPCRs 
PAR1, P2Y12, TPα, LPA5, CXCR4, PAR4, P2Y1, α2A-adrenoceptor, 
CCR4, V1A receptor, PAF receptor, FPR1, EP3 receptor, succinate, 
and 5-HT2A receptor. These comprised 38 individual SNVs of 
which 22 (58.9 %) were synonymous and 16 (42.1 %) were mis-
sense. There were no stop-gain or splice region SNVs. Thirty four 
unique SNVs were present in the 1,000 genomes and ESP popu-
lation datasets (12 with global MAF < 1 % and 22 with global MAF 
≥ 1 %) and four were undocumented. Using an identical strategy to 
the analysis of the population datasets, we classified three het-
erozygous missense SNVs as potentially damaging in the IPFD 
cases, all within P2RY12 (▶ Table 3). A wider analysis of variants 
identified in other platelet genes did not identify any single candi-
date variants that could completely account for the platelet pheno-
type of each case.
Characteristics of cases with P2Y12 variants
The P2Y12 R122H variant was identified in a female index case 1.1 
(▶ Figure 3 A) with a history of prolonged bleeding from minor 
wounds and after a vaginal delivery. There was no abnormal bleed-
ing after two other vaginal deliveries or after tonsillectomy. The 
P2Y12 P258T variant was identified in an unrelated male index 
case 2.1 (▶ Figure 3 D) who had experienced recurrent gastro-in-
testinal bleeding throughout adulthood but had no other bleeding 
symptoms. Platelets from case 1.1 and from case 2.1 showed nor-
mal shape change but reduced aggregation responses to 10–100 
µM ADP compared to healthy controls that was reversible with 10 
µM ADP (▶ Figure 3 B and E), indicating selective loss of P2Y12 
function. Compared to control subjects, platelets from both cases 
© CC-BY This is an open access article under the terms of the  
Creative Commons License, which permits use and distribution in any medium, 
 provided the original work is properly cited.
 Thrombosis and Haemostasis 113.4/2015
831Jones et al. Variation in platelet G protein-coupled receptors
also showed reduced aggregation responses to 3–30 µM epineph-
rine and 1 µg/ml collagen, but not to 3 µg/ml collagen, which are 
consistent with loss of P2Y12 function. However, there were also re-
duced aggregation responses to 0.5–1 mM arachidonic acid in case 
1.1 and reduced responses to ristocetin 1.25–1.5 mg/ml and a 
markedly reduced response to high concentration (100 µM) epi-
nephrine in case 2.1. The latter findings indicate that cases 1.1 and 
2.1 have distinct and complex aggregation phenotypes, neither of 
which can be completely explained by loss of P2Y12 function. Pla-
telets from other pedigree members 1.2 and 2.2, analysed in paral-
lel with the respective index cases, also showed reduced aggre-
gation responses to ADP compared with controls (▶ Figure 3 C 
and F). Cases 1.2 and 2.2 were subsequently shown to harbour the 
R122H and P258T variations respectively, but neither had abnor-
mal bleeding symptoms.
The P2Y12 V207A variant was identified in an asymptomatic fe-
male index case 3.1 (▶ Figure 3 G) who also harboured a P2Y12 
SNV on the same allele that predicted a T223R substitution, that 
was classified as benign. Platelets from 3.1 showed normal platelet 
shape change but reduced aggregation responses to 5–20 µM ADP 
(▶ Figure 3 H) and 5–10 µM epinephrine compared to controls. 
The maximum amplitude of responses to ADP and epinephrine 
GPCR
PAR1
PAR1
P2Y12
P2Y12
P2Y12
IP1
IP1
IP1
IP1
TPα
TPα
TPα
TPα
TPα
TPα
LPAR5
LPAR5
LPAR5
A2A
CXCR4
CXCR4
PAR4
PAR4
PAR4
Variation
rs144447562
rs372280945
rs372954515
rs367926037
rs202099742
rs147448416
rs4987262
rs201340109
rs370909150
rs34377097
rs201421330
rs372994525
rs61731124
rs374635591
rs370418735
rs149664830
rs187536858
rs374800227
rs142560733
rs368016542
rs367718547
rs374965245
rs201697829
rs2227346
Substitution
Y266C
L354F
T283I
M108L
P258T
R77C
R212C
R215C
H237R
R60L
M126T
S218G
T286M
P305L
R326W
M103K
P294L
Y298H
R293C
D84H
D193Y
G13E
R47H
F296V
Region
EL2
TM7
TM7
TM3
EL3
TM2
IL3
IL3
TM6
ICL1
TM3
TM5
TM7
TM7
CT
TM3
TM7
TM7
CT
TM2
EL2
NT
NT
TM6
Manual annotation
Tethered ligand binding region
Consensus ligand binding pocket
TM6-TM7 conserved interaction
TM3-TM6 conserved interaction; lig-
and binding pocket
Identified in subject with IPFD
Reduced surface expression (reduced 
Bmax)
Reduced surface expression (reduced 
Bmax)
Reduced surface expression (reduced 
Bmax)
Site of G protein interaction within 
helices
TM2-TM3 conserved interaction
TM3-TM2 conserved interaction
Site of G protein interaction within 
helices
Consensus ligand binding pocket
TM1-TM7 conserved interaction
Serine phosphorylation site
TM3-TM4 conserved interaction
TM1-TM7 conserved interaction
TM7-TM2 conserved interaction
Minus 5 from Thr phoshorylation site
TM1-TM2 conserved interaction
Mediates dimerization
Signal peptide
Site of cleavage of tethered ligand
TM3-TM6 conserved interaction; lig-
and binding pocket
P-SNP
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
MAPP
/
/
+
+
-
/
/
/
/
+
+
+
-
+
-
+
+
+
+
+
-
-
/
+
PhD-SNP
+
+
+
+
-
+
+
+
+
+
+
-
-
+
-
-
+
-
+
-
+
-
-
-
PP-1
+
-
+
-
+
+
+
+
+
-
-
-
+
+
+
+
+
+
+
+
+
+
+
+
PP-2
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
+
+
+
+
+
+
+
SIFT
-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
SNAP
+
-
+
+
+
+
+
+
+
+
+
+
+
+
-
+
+
+
+
+
-
+
-
+
Table 2: Potentially damaging missense variants in platelet GPCR 
genes in the 1,000 Genomes and ESP6500 databases. The table lists 
the subgroup missense SNV classified as potentially deleterious by both 
manual and computational annotation. For each missense SNV the results of 
six independent annotation tools: P-SNP (the consensus classifier), MAPP, 
PhD-SNP, PP-1, PP-2, SIFT and SNAP are indicated as + for ‘damaging’ and – 
for ‘not damaging’. / indicates the tool did not return a prediction for the 
SNV.
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were within the reference interval of responses determined from a 
panel of 30 locally recruited healthy controls, but fell within the lo-
west 10th percentile of control responses, consistent with reduced 
P2Y12 function, that was less pronounced than index cases 1.1 and 
2.1. Platelets from case 3.1 also showed reduced aggregation re-
sponses to 0.5–1 mM arachidonic acid suggesting an additional 
platelet defect. A pedigree member 3.2 with wild-type P2Y12 
showed platelet aggregation responses to ADP that were similar to 
control subjects (▶ Figure 3 I).
Analysis of the P2Y12 R122H and V207A in HEK-293 
cells
Since the R122H and V207A substitutions had not been previously 
associated with P2Y12 receptor deficiency in humans, we examin-
ed the phenotype of these substituted P2Y12 receptors in trans-
fected cells. Expression of P2Y12 R122H and V207A was observed 
predominantly at the cell surface by immunofluorescence micro-
scopy (data not shown). When cell-surface expression was quanti-
fied by ELISA, the normalised expression levels of the substituted 
receptors were almost identical to that of wild-type receptor 
(R122H mean 113 % ± S. E. M. 14.5 % and V207A 97.5 % ± 7.9 %; 
▶ Figure 4 A) indicating that neither substitution significantly af-
fected P2Y12 receptor trafficking. When P2Y12 receptor function 
was tested by measuring the ability of ADP to reduce cellular 
cAMP levels, the substituted P2Y12 receptors showed less reduc-
tion in cAMP at ADP concentrations of 1 µM to 10nM compared 
to P2Y12 wild-type (p=0.013 for R122H and p=0.019 for V207A; 1 
way ANOVA: ▶ Figure 4 B). These data indicate that both substi-
tutions reduce P2Y12 function, with a weaker effect from P2Y12 
V207A substitution, consistent with the less marked platelet aggre-
gation defect.
GPCR
PAR4
α2A
α2A
α2A
CCR4
DP1
DP1
V1A
V1A
V1A
PAF
FPR1
FPR1
FPR1
succi-
nate
succi-
nate
succi-
nate
succi-
nate
5-HT2A
Variation
rs111890288
rs149350078
rs370313798
rs375454021
rs200003145
rs145604058
rs370262391
rs180760072
rs369710823
rs377107751
rs139524224
rs369354920
rs149931707
rs368075541
rs371440145
rs374436394
rs142256005
rs142852744
rs375024989
Substitution
S329C
I234M
R383G
V390M
A240V
T69M
A127T
F133C
M145T
V153L
R229Q
D122H
R123H
R238H
N41K
I240N
R252Q
R291Q
N38K
Region
TM7
TM5
TM6
TM6
TM6
TM2
TM3
TM3
TM3
TM3
TM6
TM3
TM3
TM6
TM1
TM6
TM6
TM7
NT
Manual annotation
Consensus ligand binding pocket
Site of G protein interaction within 
helices
Site of G protein interaction within 
helices
Site of G protein interaction within 
helices
Site of G protein interaction within 
helices
TM1-TM2 conserved interaction
TM3-TM5 conserved interaction
TM3-TM4 conserved interaction
TM3-TM2 conserved interaction
Site of G protein interaction within 
helices
Site of G protein interaction within 
helices
E/DRY motif
Site of G protein interaction within 
helices
Site of G protein interaction within 
helices
TM1-TM2 conserved interaction
TM3-TM6 conserved interaction
Agonist dependent activation
Agonist dependent activation; 
TM6-TM7 interaction
N-linked glycosylation site
P-SNP
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
MAPP
-
+
+
+
-
+
+
-
-
+
+
+
-
+
+
-
-
-
PhD-SNP
+
+
+
-
+
-
+
+
+
+
-
-
-
+
-
+
+
-
PP-1
-
+
+
+
+
-
-
-
-
-
+
+
-
+
+
+
+
+
PP-2
+
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
+
+
SIFT
+
+
+
+
+
+
+
+
-
+
+
+
+
+
+
+
+
+
SNAP
-
+
+
-
-
-
+
-
-
-
+
+
-
+
+
-
+
+
Table 2: Continued
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Table 3: Potentially damaging missense SNV in P2RY12 in cases with IPFD. This table lists the missense SNV found in P2RY12 in cases with a demon-
strable platelet aggregation defect. For each missense SNV the results of six independent annotation tools: P-SNP (the consensus classifier), MAPP, PhD-SNP, 
PP-1, PP-2, SIFT and SNAP are indicated as + for ‘damaging’ and – for ‘not damaging’.
Substitution
R122H
P258T
V207A
Variation
novel
rs202099742
rs370983746
Manual annotation
DRY motif
TM6; adjacent to Y259 that 
 contributes to ligand binding
TM5; adjacent to C208 that has 
multiple binding contacts with TM3
P-SNP
+
+
+
MAPP
+
-
+
PhD-SNP
+
-
-
PP-1
+
+
-
PP-2
+
+
+
SIFT
+
+
+
SNAP
+
+
+
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Discussion
We have reported the results of a unique survey of coding and 
splice region SNVs in 18 platelet GPCR genes from 7,595 exomes 
in the 1,000 genomes and ESP databases and from 31 cases with 
IPFD. Our main findings were that: (i) in the population data-
bases, the GPCR gene target regions contained potentially damag-
ing SNVs that were individually rare, but collectively numerous; ii) 
the potentially damaging SNVs were diverse and were predicted to 
alter GPCR activity through several mechanisms, and, iii) a repre-
sentative collection of cases with IPFD also had SNVs in platelet 
GPCR genes, including potentially damaging variants affecting 
P2Y12 in three cases.
Our strategy for identifying potentially damaging SNVs was 
based on computational annotation using six bioinformatic tools 
with different methodologies (22), complemented by manual an-
notation using resources that are unique to GPCRs. These in-
cluded the GPCRDB database that catalogues previous GPCR mu-
tagenesis experiments, the high resolution structures for the PAR1, 
A2A and P2Y12 receptors (26–28) and the consensus structure for 
Class A GPCRs (25) that provides structural data for GPCRs with 
unsolved crystal structures. Combined computational and manual 
annotation has provided a valuable insight into the diversity and 
impact of rare variants in human GPCR genes. However, our 
analysis has focussed on missense rather than synonymous coding 
region SNVs. Since 6 % of all synonymous SNVs in the ESP exome 
dataset were computed to be potentially damaging, primarily 
through codon usage effects (10, 29), our analysis is likely to have 
underestimated the overall burden of GPCR gene variation.
Within the ESP and 1,000 genomes databases, we found 740 
SNVs in the GPCR gene target regions, of which 56 % were mis-
sense and 70 % had a global MAF < 0.05 % or were singleton rec-
ords. These characteristics are similar to the entire ESP exome da-
taset comprising > 500,000 SNVs, of which 58 % are missense and 
72 % are present in only three alleles or less (10), indicating an 
exome-wide abundance of rare missense variants. Our prediction 
that 21 % of SNVs in the GPCR gene target regions were poten-
tially damaging, is also similar to exome-wide estimates of 17 % 
determined by computation (10). One noteworthy finding from 
our survey is that the platelet GPCR genes contained a median of 
41.5 SNVs per coding region, compared with 24 SNVs per coding 
region exome-wide (10). The high variation rate in GPCR genes 
cannot be explained by differences in the length of coding region 
because the GPCR genes had median coding length 1121 bp, simi-
lar to the exome median of 1,100 bp (30). However, this difference 
could be related to GC content (31) which was 56.4 % in platelet 
GPCR genes compared to 51 % exome-wide (32). Consistent with 
this, the GPCR genes F2RL3 and PTGIR with high GC content, 
had more SNVs than others with lower GC content, although this 
trend was inconsistent across all platelet GPCRs. We also showed 
that SNVs classified as potentially damaging were more common 
in gene regions encoding GPCR TM helices and CT intracellular 
regions compared to other areas. This reflects the essential roles of 
the TM helices in maintaining GPCR tertiary structure and defin-
ing the ligand binding and G-protein interaction sites (25) and the 
CT intracellular regions in regulating GPCR signalling and traf-
ficking (33).
Consistent with the population databases, the 31 cases with 
IPFD also harboured rare missense SNVs in genes encoding the 
stimulatory platelet GPCRs. Although these were represented in 
all of the target GPCR genes, the three variants that were predicted 
to be potentially damaging were exclusively in P2RY12 and oc-
curred as heterozygous traits.
These included the P2Y12 P258T substitution which occurs ad-
jacent to Y259 in TM6 that is required for ligand binding (28). 
This substitution was identified and characterised previously in an 
unrelated IPFD pedigree who also displayed reduced platelet re-
sponses to ADP (34), identical to the phenotype in the P2Y12 
P258T pedigree in our study. Since this independent data provides 
good evidence that the P258T variation is causally related to loss of 
P2Y12 receptor function, we performed no further characteri-
sation.
The other observed P2Y12 variants had not been previously re-
ported. These included an SNV predicting an R122H substitution 
within the P2Y12 DRY motif which has multiple postulated roles 
in regulating receptor conformation, G-protein interactions and 
receptor trafficking (35). This substitution also occurs at a residue 
affected by a different substitution (P2Y12 R122C) in a previously 
reported IPFD pedigree with P2Y12 dysfunction (17). The P2Y12 
V207A substitution affects a residue not previously associated with 
an IPFD, but which is adjacent to C208 in TM5 which has multiple 
interactions with TM3 and is, thereby, required for receptor struc-
tural integrity (25). Consistent with these significant structural 
predictions, we confirmed that the P2Y12 V207A and R122H sub-
stitutions were responsible for loss of P2Y12 receptor function by 
demonstrating diminished ADP-mediated reduction in 
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P2Y12 P258T substitution. E) LTA response to 10–100 µM ADP in platelet-rich 
plasma from 2.1 and an HC. F) LTA responses to 30 µM ADP in 2.2 and a HC. 
G) The pedigree of the index case 3.1 who was heterozygous for the P2Y12 
V207A and T223R substitutions (indicated by half black and half grey shad-
ing), showing pedigree member 3.2 with wild-type P2Y12. H) LTA  response to 
2–10 µM ADP in platelet-rich plasma from 1.1 and an HC. I) LTA responses to 
2 µM ADP in 3.2 and a HC.
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Figure 3: Platelet phenotype in cases with potentially damaging 
SNV in P2RY12. A) The pedigree of index case 1.1, who was heterozygous 
for the P2Y12 R122H substitution (half back shading), showing pedigree 
member 1.2, also with the P2Y12 R122H substitution. B) Light transmission 
aggregation (LTA) responses to 10–100 µM ADP in platelet-rich plasma from 
1.1 and a healthy control (HC). C) LTA responses to 30 µM ADP in 1.2. D) The 
pedigree of index case 2.1, who was heterozygous for the P2Y12 P258T sub-
stitution (half black shading) showing pedigree member 2.2, also with the 
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 cytoplasmic cAMP levels in transfected cells, which is a sensitive 
and highly specific measure of P2Y12 function (36). Our demon-
stration that cell surface expression of the substituted P2Y12 re-
ceptors was the same as wild-type suggest that both V207A and 
R122H disrupt function by impairing ligand binding, receptor 
 activation or signal transduction, rather than by affecting receptor 
trafficking.
It is noteworthy that in the IPFD cases in this series, the R122H 
and P258T substitutions, and to a less pronounced extent the 
V207A substitution, were associated with reduced platelet 
 responses to ADP consistent with impaired P2Y12 function. Pla-
telet responses to low concentrations of other activating agonists 
were also reduced, in keeping with impaired P2Y12-mediated 
positive feedback from ADP released via dense granules, and simi-
Figure 4: Cell surface 
expression and func-
tion of P2Y12 R122H 
and V207A in trans-
fected cells. A) Cell sur-
face expression of HA-
tagged P2Y12 wild-type 
(WT), R122H and V207A 
was determined in trans-
fected cells by ELISA 
using an anti-HA mono-
clonal antibody. Mean ex-
pression levels ± SEM in 
three independent experi-
ments are presented, nor-
malised to expression of 
WT P2Y12. B) The ability 
of P2Y12 WT, R122H and 
V207A to decrease cellu-
lar cAMP levels was de-
termined in transfected 
cells by measuring resid-
ual cAMP by ELISA after 
incubation with the indi-
cated concentrations of 
ADP. Data from three in-
dependent experiments 
are presented as the per-
centage inhibition (mean 
± S. E.M) of the basal 
cAMP level in forskolin-
treated cells.
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lar to previous IPFD cases with loss-of-function P2Y12 variants 
(11, 34, 37). Despite this platelet phenotype, there was an incon-
sistent relationship between the heterozygous P2Y12 variants and 
abnormal bleeding, suggesting that partial loss of P2Y12 function 
alone is insufficient to affect haemostasis. It is also noteworthy that 
in all three index cases with potentially damaging P2Y12 variants, 
there were abnormal responses to other activating agonists that 
may not be explained solely by loss of P2Y12 function because of 
the magnitude of the other defects. Our data do not allow us to ex-
clude a dominant negative effect from the observed heterozygous 
P2Y12 variants, or a further non-coding P2Y12 variant in trans 
that reduces expression of the other allele. However, a more plaus-
ible explanation is that in addition to a variant affecting P2Y12, the 
IPFD cases also harboured loss-of-function variants in other pla-
telet genes that contributed to bleeding and to the complex labora-
tory phenotypes. The concept that some IPFD have complex heri-
tability is supported by previous descriptions of pedigrees with 
phenotypes that are the composite effect of independent variants 
affecting P2Y12 and PAR1 (17) and P2Y12 and von Willebrand 
factor (11). We speculate that the apparent over-representation of 
P2Y12 defects in our case series and in these previous reports, may 
reflect that clinical diagnostic LTA agonist panels have greater sen-
sitivity for defective stimulatory GPCRs in non-redundant feed-
back pathways such as P2Y12, than other GPCRs, thereby intro-
ducing a selection effect.
Through a systematic analysis of platelet GPCR genes, we have 
highlighted the burden of rare SNVs in the general population and 
in selected patients with IPFDs. The variety and burden of poten-
tially damaging SNVs in the healthy population recruited into the 
1,000 genome and ESP databases highlight the incomplete pen-
etrance of these variants. This suggests the possibility that mild 
IPFDs are more frequent in the general population, but may com-
monly go unnoticed until a challenge, such as childbirth, surgery 
or initiation of antiplatelet therapy, is applied. The spread of bleed-
ing manifestations even in patients diagnosed with IPFDs and har-
bouring identical SNVs also highlights the challenges of applying 
genetic screening with platelet function testing approaches to large 
populations. Rare variants affecting GPCR function may be solely 
responsible for the phenotypes of some isolated pedigrees with 
IPFD, but could also contribute to complex defects caused by vari-
ants in other platelet genes.
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